Uncoupling angiogenesis and inflammation in peripheral artery disease with therapeutic peptide-loaded microgels

Biomaterials

Volumn 35, Issue 36, 2014, Pages 9635-9648

  Zachman, Angela L ^a   Wang, Xintong ^a   Tucker Schwartz, Jason M ^a   Fitzpatrick, Sean T ^a   Lee, Sue H ^a   Guelcher, Scott A ^a   Skala, Melissa C ^a   Sung, Hak Joon ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

Angiogenesis; Inflammation; Peptide; Polycaprolactone; Polyethylene glycol; Polymer

Indexed keywords

DISEASES; GELS; MEDICAL APPLICATIONS; PATHOLOGY; POLYCAPROLACTONE; POLYETHYLENE GLYCOLS; POLYMERS;

ANGIOGENESIS; ANGIOGENIC GROWTH FACTORS; INFLAMMATION; INFLAMMATORY RESPONSE; MINIMALLY INVASIVE WAYS; PERIPHERAL ARTERY DISEASE; SURGICAL INTERVENTIONS; THERAPEUTIC PEPTIDES;

PEPTIDES;

BIOMATERIAL; GELATINASE B; MICROGEL; PEPTIDE C16; PEPTIDE DERIVATIVE; SERASPENIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANGIOGENIC FACTOR; ANTIINFLAMMATORY AGENT; DRUG CARRIER; MATRIX METALLOPROTEINASE INHIBITOR; OLIGOPEPTIDE; POLYCAPROLACTONE; POLYESTER;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; MINIMALLY INVASIVE PROCEDURE; MOUSE; MUSCLE REGENERATION; NONHUMAN; PERFUSION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; CHEMISTRY; COMPLICATION; DRUG EFFECTS; IMMUNOLOGY; INJECTION; PERIPHERAL ARTERIAL DISEASE; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL LINE; DRUG CARRIERS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; INFLAMMATION; INJECTIONS; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASE INHIBITORS; MICE; NEOVASCULARIZATION, PHYSIOLOGIC; OLIGOPEPTIDES; PERIPHERAL ARTERIAL DISEASE; POLYESTERS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84922360760     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.08.011     Document Type: Article

References (72)

1. Roger V.L., Go A.S., Lloyd-Jones D.M., Adams R.J., Berry J.D., Brown T.M., et al. Heart disease and stroke statistics - 2011 update: a report from the American Heart Association. Circulation 2011, 123:e18-e209.
2. Pacilli A., Faggioli G., Stella A., Pasquinelli G. An update on therapeutic angiogenesis for peripheral vascular disease. Ann Vasc Surg 2010, 24:258-268.
3. Gardner AW, Parker DE, Montgomery PS, Sosnowska D, Casanegra AI, Ungvari Z, etal. Gender and racial differences in endothelial oxidative stress and inflammation in patients with symptomatic peripheral artery disease. J Vasc Surg.
4. Signorelli S.S., Fiore V., Malaponte G. Inflammation and peripheral arterial disease: the value of circulating biomarkers. Int J Mol Med 2014, 33:777-783. (Review).
5. Llorente-Cortes V., de Gonzalo-Calvo D., Orbe J., Paramo J.A., Badimon L. Signature of subclinical femoral artery atherosclerosis in peripheral blood mononuclear cells. Eur J Clin Invest 2014, 44:539-548.
6. Alexandru N., Popov D., Georgescu A. Platelet dysfunction in vascular pathologies and how can it be treated. Thromb Res 2012, 129:116-126.
7. Bennett P.C., Silverman S., Gill P., Lip G.Y.H. Peripheral artery disease and angiogenesis: a link between angiogenesis and atherothrombosis therapeutic angiogenesis for vascular diseases 2011, 339-359. Springer, Netherlands. M. Slevin (Ed.).
8. Grisar J.C., Haddad F., Gomari F.A., Wu J.C. Endothelial progenitor cells in cardiovascular disease and chronic inflammation: from biomarker to therapeutic agent. Biomark Med 2011, 5:731-744.
9. Fleiner M., Kummer M., Mirlacher M., Sauter G., Cathomas G., Krapf R., et al. Arterial neovascularization and inflammation in vulnerable patients - early and late signs of symptomatic atherosclerosis. Circulation 2004, 110:2843-2850.
10. Bailey L.O., Washburn N.R., Simon C.G., Chan E.S., Wang F.W. Quantification of inflammatory cellular responses using real-time polymerase chain reaction. JBiomed Mater Res A 2004, 69A:305-313.
11. Hu W.J., Eaton J.W., Tang L.P. Molecular basis of biomaterial-mediated foreign body reactions. Blood 2001, 98:1231-1238.
12. Zachman A.L., Crowder S.W., Ortiz O., Zienkiewicz K., Bronikowski C.M., Yu S.S., et al. Pro-angiogenic and anti-inflammatory regulation by functional peptides loaded in polymeric implants for soft tissue regeneration. Tissue Eng Part A 2012, 19:437-447.
13. Kuratomi Y., Nomizu M., Tanaka K., Ponce M.L., Komiyama S., Kleinman H.K., et al. Laminin gamma 1 chain peptide, C-16 (KAFDITYVRLKF), promotes migration, MMP-9 secretion, and pulmonary metastasis of B16-F10 mouse melanoma cells. Br J Cancer 2002, 86:1169-1173.
14. Ponce M.L., Nomizu M., Delgado M.C., Kuratomi Y., Hoffman M.P., Powell S., et al. Identification of endothelial cell binding sites on the laminin gamma 1 chain. Circ Res 1999, 84:688-694.
15. Malinda K.M., Nomizu M., Chung M., Delgado M., Kuratomi Y., Yamada Y., et al. Identification of laminin alpha1 and beta1 chain peptides active for endothelial cell adhesion, tube formation, and aortic sprouting. FASEB J 1999, 13:53-62.
16. Yang F., Yang X.P., Liu Y.H., Xu J., Cingolani O., Rhaleb N.E., et al. Ac-SDKP reverses inflammation and fibrosis in rats with heart failure after myocardial infarction. Hypertension 2004, 43:229-236.
17. Tziampazis E., Kohn J., Moghe P.V. PEG-variant biomaterials as selectively adhesive protein templates: model surfaces for controlled cell adhesion and migration. Biomaterials 2000, 21:511-520.
18. Liu E., Treiser M.D., Patel H., Sung H.J., Roskov K.E., Kohn J., et al. High-content profiling of cell responsiveness to graded substrates based on combinyatorially variant polymers. Comb Chem High Throughput Screen 2009, 12:646-655.
19. Yu S.S., Koblin R.L., Zachman A.L., Perrien D.S., Hofmeister L.H., Giorgio T.D., et al. Physiologically relevant oxidative degradation of oligo(proline) cross-linked polymeric scaffolds. Biomacromolecules 2011, 12:4357-4366.
20. Gupta M.K., Walthall J.M., Venkataraman R., Crowder S.W., Jung D.K., Yu S.S., et al. Combinatorial polymer electrospun matrices promote physiologically-relevant cardiomyogenic stem cell differentiation. PLoS One 2011, 6:e28935.
21. Gutowska A., Jeong B., Jasionowski M. Injectable gels for tissue engineering. Anat Rec 2001, 263:342-349.
22. Minh K.N., Lee D.S. Injectable biodegradable hydrogels. Macromol Biosci 2010, 10:563-579.
23. Chen L.F., Greene W.C. Shaping the nuclear action of NF-kappa B. Nat Rev Mol Cell Biol 2004, 5:392-401.
24. Ghosh S., Karin M. Missing pieces in the NF-kappa B puzzle. Cell 2002, 109:S81-S96.
25. Li H., Liang H.P., Castrillon D.H., DePinho R.A., Olson E.N., Liu Z.P. FoxO4 regulates tumor necrosis factor alpha-directed smooth muscle cell migration by activating matrix metalloproteinase 9 gene transcription. Mol Cell Biol 2007, 27:2676-2686.
26. Tseng H.C., Lee I.T., Lin C.C., Chi P.L., Cheng S.E., Shih R.H., et al. IL-1 beta promotes corneal epithelial cell migration by increasing MMP-9 expression through NF-kappa B- and AP-1-dependent pathways. PLoS One 2013, 8.
27. Bazzoni F., Beutler B. The tumor necrosis factor ligand and receptor families. NEngl J Med 1996, 334:1717-1725.
28. Sherry B., Cerami A. Cachectin tumor necrosis factor exerts endocrine, paracrine, and autocrine control of inflammatory responses. JCell Biol 1988, 107:1269-1277.
29. Beutler B., Greenwald D., Hulmes J.D., Chang M., Pan Y.C.E., Mathison J., et al. Identity of tumor necrosis factor and the macrophage-secreted factor cachectin. Nature 1985, 316:552-554.
30. Palladino M.A., Bahjat F.R., Theodorakis E.A., Moldawer L.L. Anti-TNF-alpha therapies: the next generation. Nat Rev Drug Discov 2003, 2:736-746.
31. Maiuri M.C., Tajana G., Iuvone T., De Stefano D., Mele G., Ribecco M.T., et al. Nuclear factor-kappa B regulates inflammatory cell apoptosis and phagocytosis in rat carrageenin-sponge implant model. Am J Pathol 2004, 165:115-126.
32. Crowder S.W., Gupta M.K., Hofmeister L.H., Zachman A.L., Sung H.-J. Modular polymer design to regulate phenotype and oxidative response of human coronary artery cells for potential stent coating applications. Acta Biomater 2012, 8:559-569.
33. Gimenez S., Ponsart S., Coudane J., Vert M. Synthesis, properties and invitro degradation of carboxyl-bearing PCL. JBioact Compat Polym 2001, 16:32-46.
34. Limbourg A., Korff T., Napp L.C., Schaper W., Drexler H., Limbourg F.P. Evaluation of postnatal arteriogenesis and angiogenesis in a mouse model of hind-limb ischemia. Nat Protoc 2009, 4:1737-1748.
35. Mercanzini A., Reddy S.T., Velluto D., Colin P., Maillard A., Bensadoun J.-C., et al. Controlled release nanoparticle-embedded coatings reduce the tissue reaction to neuroprostheses. JControl Release 2010, 145:196-202.
36. Wardell K., Jakobsson A., Nilsson G.E. Laser Doppler perfusion imaging by dynamic light scattering. IEEE Trans Biomed Eng 1993, 40:309-316.
37. Poole K.M., Tucker-Schwartz J.M., Sit W.W., Walsh A.J., Duvall C.L., Skala M.C. Quantitative optical imaging of vascular response invivo in a model of peripheral arterial disease. Am J Physiol Heart Circ Physiol 2013, 305:H1168-H1180.
38. Johnson C., Sung H.J., Lessner S.M., Fini M.E., Galis Z.S. Matrix metalloproteinase-9 is required for adequate angiogenic revascularization of ischemic tissues - potential role in capillary branching. Circ Res 2004, 94:262-268.
39. Sung H.J., Johnson C.E., Lessner S.M., Magid R., Drury D.N., Galis Z.S. Matrix metalloproteinase 9 facilitates collagen remodeling and angiogenesis for vascular constructs. Tissue Eng 2005, 11:267-276.
40. Foukas L.C., Katsoulas H.L., Paraskevopoulou N., Metheniti A., Lambropoulou M., Marmaras V.J. Phagocytosis of Escherichia coli by insect hemocytes requires both activation of the Ras/mitogen-activated protein kinase signal transduction pathway for attachment and beta3 integrin for internalization. JBiol Chem 1998, 273:14813-14818.
41. Biscetti F., Pecorini G., Straface G., Arena V., Stigliano E., Rutella S., et al. Cilostazol promotes angiogenesis after peripheral ischemia through a VEGF-dependent mechanism. Int J Cardiol 2012.
42. Dace D.S., Khan A.A., Kelly J., Apte R.S. Interleukin-10 promotes pathological angiogenesis by regulating macrophage response to hypoxia during development. PLoS One 2008, 3:e3381.
43. Raghu H., Sodadasu P.K., Malla R.R., Gondi C.S., Estes N., Rao J.S. Localization of uPAR and MMP-9 in lipid rafts is critical for migration, invasion and angiogenesis in human breast cancer cells. BMC Cancer 2010, 10.
44. Yang F., Li X., Wang L.K., Wang L.W., Han X.Q., Zhang H., et al. Inhibitions of NF-kappaB and TNF-alpha result in differential effects in rats with acute on chronic liver failure induced by D-Gal and LPS. Inflammation 2014.
45. Zachman A.L., Page J.M., Prabhakar G., Guelcher S.A., Sung H.J. Elucidation of adhesion-dependent spontaneous apoptosis in macrophages using phase separated PEG/polyurethane films. Acta Biomater 2013, 9:4964-4975.
46. Chalothorn D., Faber J.E. Strain-dependent variation in collateral circulatory function in mouse hindlimb. Physiol Genomics 2010, 42:469-479.
47. Maderna P., Godson C. Phagocytosis of apoptotic cells and the resolution of inflammation. Biochim Biophys Acta Mol Basis Dis 2003, 1639:141-151.
48. Voskuil M., van Royen N., Hoefer I.E., Seidler R., Guth B.D., Bode C., et al. Modulation of collateral artery growth in a porcine hindlimb ligation model using MCP-1. Am J Physiol Heart Circ Physiol 2003, 284:H1422-H1428.
49. Seidler R.W., Allgauer S., Ailinger S., Sterner A., Dev N., Rabussay D., et al. Invivo human MCP-1 transfection in porcine arteries by intravascular electroporation. Pharm Res 2005, 22:1685-1691.
50. Sun H., Wang X., Hu X., Yu W., You C., Hu H., et al. Promotion of angiogenesis by sustained release of rhGM-CSF from heparinized collagen/chitosan scaffolds. JBiomed Mater Res B Appl Biomater 2012, 100:788-798.
51. Vajanto I., Rissanen T.T., Rutanen J., Hiltunen M.O., Tuomisto T.T., Arve K., et al. Evaluation of angiogenesis and side effects in ischemic rabbit hindlimbs after intramuscular injection of adenoviral vectors encoding VEGF and LacZ. JGene Med 2002, 4:371-380.
52. Grochot-Przeczek A., Dulak J., Jozkowicz A. Therapeutic angiogenesis for revascularization in peripheral artery disease. Gene 2013, 525:220-228.
53. Das S., Singh G., Baker A.B. Overcoming disease-induced growth factor resistance in therapeutic angiogenesis using recombinant co-receptors delivered by a liposomal system. Biomaterials 2014, 35:196-205.
54. Li J., Wei Y., Liu K., Yuan C., Tang Y., Quan Q., et al. Synergistic effects of FGF-2 and PDGF-BB on angiogenesis and muscle regeneration in rabbit hindlimb ischemia model. Microvasc Res 2010, 80:10-17.
55. Lazarous D.F., Unger E.F., Epstein S.E., Stine A., Arevalo J.L., Chew E.Y., et al. Basic fibroblast growth factor in patients with intermittent claudication: results of a phase I trial. JAm Coll Cardiol 2000, 36:1239-1244.
56. Cooper L.T., Hiatt W.R., Creager M.A., Regensteiner J.G., Casscells W., Isner J.M., et al. Proteinuria in a placebo-controlled study of basic fibroblast growth factor for intermittent claudication. Vasc Med 2001, 6:235-239.
57. Lederman R.J., Mendelsohn F.O., Anderson R.D., Saucedo J.F., Tenaglia A.N., Hermiller J.B., et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet 2002, 359:2053-2058.
58. Marui A., Tabata Y., Kojima S., Yamamoto M., Tambara K., Nishina T., et al. Novel approach to therapeutic angiogenesis for patients with critical limb ischemia by sustained release of basic fibroblast growth factor using biodegradable gelatin hydrogel - an initial report of the phase I-IIa study. Circ J 2007, 71:1181-1186.
59. Speer D.P., Chvapil M., Eskelson C.D., Ulreich J. Biological effects of residual glutaraldehyde in glutaraldehyde-tanned collagen biomaterials. JBiomed Mater Res 1980, 14:753-764.
60. Huanglee L.L.H., Cheung D.T., Nimni M.E. Biochemical-changes and cytotoxicity associated with the degradation of polymeric glutaraldehyde derived cross-links. JBiomed Mater Res 1990, 24:1185-1201.
61. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
62. Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation 2002, 105:1135-1143.
63. Libby P., Ridker P.M. Inflammation and atherothrombosis: from population biology and bench research to clinical practice. JAm Coll Cardiol 2006, 48:A33-A46.
64. Fan W., Li C., Qin X., Wang S., Da H., Cheng K., et al. Adipose stromal cell and sarpogrelate orchestrate the recovery of inflammation-induced angiogenesis in aged hindlimb ischemic mice. Aging Cell 2013, 12:32-41.
65. Hamburg N.M., Leeper N.J. Therapeutic potential of modulating microRNA in peripheral artery disease. Curr Vasc Pharmacol 2013.
66. Jaipersad A.S., Lip G.Y.H., Silverman S., Shantsila E. The role of monocytes in angiogenesis and atherosclerosis. J Am Coll Cardiol 2014, 63:1-11.
67. Imhof B.A., Aurrand-Lions M. Angiogenesis and inflammation face off. Nat Med 2006, 12:171-172.
68. Drexler W. Ultrahigh-resolution optical coherence tomography. JBiomed Opt 2004, 9:47-74.
69. Camargo L.D., Babelova A., Mieth A., Weigert A., Mooz J., Rajalingam K., et al. Endo-PDI is required for TNF alpha-induced angiogenesis. Free Radic Biol Med 2013, 65:1398-1407.
70. Siwik D.A., Chang D.L.F., Colucci W.S. Interleukin-1 beta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts invitro. Circ Res 2000, 86:1259-1265.
71. Bond M., Fabunmi R.P., Baker A.H., Newby A.C. Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B. FEBS Lett 1998, 435:29-34.
72. Lee C.W., Lin C.C., Lin W.N., Liang K.C., Luo S.F., Wu C.B., et al. TNF-alpha induces MMP-9 expression via activation of Src/EGFR, PDGFR/PI3K/Akt cascade and promotion of NF-kappa B/p300 binding in human tracheal smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2007, 292:L799-L812.